Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Syndax Pharmaceuticals (SNDX) Pipeline Is Strong Enough To Offset Entinostat Delay - Baird
March 8, 2019 6:24 AM ESTBaird analyst, Madhu Kumar, reiterated his Outperform rating on shares of Syndax Pharmaceuticals (NASDAQ: SNDX) after the company announced the delay of the firm's immunooncology (I-O) combination programs with lead asset, histone deacetylase (HDAC)
inhibitor entinostat. Despite this delay, the analyst remains bullish on... More
Syndax Pharmaceuticals (SNDX) PT Raised to $16 at Nomura/Instinet
March 8, 2019 5:46 AM ESTNomura/Instinet analyst Christopher Marai raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $16.00 (from $12.00) while maintaining a Buy rating.
... MoreSyndax Pharmaceuticals (SNDX) PT Raised to $16 at Nomura/Instinet
March 8, 2019 4:33 AM ESTNomura/Instinet analyst Christopher Marai raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $16.00 (from $12.00) while maintaining a Buy rating.
... MoreAfter-Hours Movers 03/07: (JYNT) (MDCA) (COST) Higher; (EB) (WTER) (FIZZ) (more...)
March 7, 2019 5:42 PM ESTToday's After-Hours Movers
Eventbrite (NYSE: EB) 22.1% LOWER; reported Q4 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $75.9 million versus the consensus estimate of $73.22 million. Eventbrite sees Q1 2019 revenue of $80-84 million, versus the consensus of $91.1 million.
T2 Biosystems (NASDAQ: TTOO) 17.2% LOWER; Revenue for the quarter came in at $1.8 million versus the consensus estimate of $2.67 million.
The Alkaline Water Company Inc. (NASDAQ:... More
Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 3c; Provides Q1 & FY19 Operating Guidance
March 7, 2019 4:27 PM ESTSyndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.70), $0.03 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $380 thousand versus the consensus estimate of $390 thousand.
"We expect the coming months to be a very exciting, milestone-rich time for Syndax as we continue to work towards our mission of realizing a future in which cancer patients live longer and better lives than previously possible," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "We remain highly encouraged by the potential for a positive overall survival readout in E2112, our Phase 3... More
